Home

חן לא להתגלח teva new ms drug בונוס סדרה רב שנתי

Court invalidates four of Teva's Copaxone patents; company to appeal - Philadelphia Business Journal
Court invalidates four of Teva's Copaxone patents; company to appeal - Philadelphia Business Journal

Teva fails to reclassify MS drug to thwart generics
Teva fails to reclassify MS drug to thwart generics

Teva scraps Heptares migraine pact as lead drug nears clinic | Fierce Biotech
Teva scraps Heptares migraine pact as lead drug nears clinic | Fierce Biotech

Blues plan sues Teva over marketing for its MS drug Copaxone
Blues plan sues Teva over marketing for its MS drug Copaxone

Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much | The Motley Fool
Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much | The Motley Fool

Teva knocked as competition fears grow for MS drug | Financial Times
Teva knocked as competition fears grow for MS drug | Financial Times

Teva's COPAXONE Approved in Japan for the Prevention of Relapse Remitting Multiple Sclerosis
Teva's COPAXONE Approved in Japan for the Prevention of Relapse Remitting Multiple Sclerosis

Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)
Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)

Teva Pharmaceuticals names former Sandoz exec to CEO post
Teva Pharmaceuticals names former Sandoz exec to CEO post

Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone
Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone

Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times
Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times

Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - Canada
Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - Canada

Teva, Takeda To Commercialize Multiple Sclerosis Drug - Asian Scientist Magazine
Teva, Takeda To Commercialize Multiple Sclerosis Drug - Asian Scientist Magazine

Teva Found Liable for Fueling Opioid Addiction in New York - WSJ
Teva Found Liable for Fueling Opioid Addiction in New York - WSJ

A Risk Evaluation Of Biogen's Multiple Sclerosis Segment (NASDAQ:BIIB) | Seeking Alpha
A Risk Evaluation Of Biogen's Multiple Sclerosis Segment (NASDAQ:BIIB) | Seeking Alpha

Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times
Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times

Targeted Delivery Platforms for the Treatment of Multiple Sclerosis | Molecular Pharmaceutics
Targeted Delivery Platforms for the Treatment of Multiple Sclerosis | Molecular Pharmaceutics

US states sue Teva for price-fixing in 'multi-billion dollar fraud' | The Times of Israel
US states sue Teva for price-fixing in 'multi-billion dollar fraud' | The Times of Israel

Better Late Than Never: Novartis, Momenta Win FDA Approval for Delayed MS Drug | BioSpace
Better Late Than Never: Novartis, Momenta Win FDA Approval for Delayed MS Drug | BioSpace

Novartis' Gilenya tops Teva giant Copaxone in head-to-head MS study | Fierce Pharma
Novartis' Gilenya tops Teva giant Copaxone in head-to-head MS study | Fierce Pharma

Teva Pharmaceuticals - Wikipedia
Teva Pharmaceuticals - Wikipedia

Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development
Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development